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Studies have reported that Parkinson’s disease (PD) is associated with impairments
on cognitive visual tasks. However, the effects of dopamine on cognitive vision remain
equivocal. The purpose of this study was to examine performance on cognitive vision
tasks in persons with PD and the effects of levodopa on these tasks. Fourteen
individuals with PD and 14 age- and sex-matched healthy older adults completed the
study. Participants with PD completed the visual tasks following a 12-h withdrawal of
dopaminergic medication and again 1 h after taking 1.5 times their normal dose of
levodopa. Healthy older adults completed the visual tasks twice using the same session
format. Five complex visual tasks were completed, including line discrimination, object
discrimination, facial discrimination, visual working memory, and object rotation. The
Unified Parkinson’s Disease Rating Scale was also collected off and on medication.
Participants with PD performed significantly worse than the healthy older adults across
all five visual tasks. There were no significant differences in performance between
the off and on medication state in persons with PD. This finding indicates either that
dopamine deficiency may not be responsible for cognitive visual impairments in PD or
that cognitive visual impairments in PD might simply be the result of deficits in more basic
visual processing.
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INTRODUCTION
A broad spectrum of visual symptoms has been observed in persons with Parkinson’s Disease (PD).
Indeed, 77% of individuals with PD report at least one recurring visual symptom, while 43% report
two or more (1), but the research findings on visual processing impairments in PD, along with the
effect of medication, remain equivocal. Thus, there is a need to better understand visual impairment
in persons with PD.
Deficits in low level visual processing are evident in persons with PD, including impairments
in visual acuity (2, 3), contrast sensitivity (4), and line discrimination (4–6). Impairments at these
lower levels of visual processing may be affecting downstream visual processes such as object and
face recognition, but evidence regarding the existence of high level visual processing deficits in
PD is conflicting. While some studies have found that persons with PD have difficulty identifying
objects (4), others have found minimal, if any, deficits in recognizing objects (7). Similarly, studies
examining face recognition in persons with PD have found impairments (8, 9), while others
have not (10). In some cases these deficits in object and facial recognition may be explained by
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impairments in visual working memory. Indeed, research has
shown that persons with PD score significantly lower than HOAs
on remembering novel faces for short durations (9). Finally,
studies have indicated that PD is associated with impairments of
mental rotation of objects (11), but others have failed to observe
deficits in mental rotation (12).
Given the equivocal research on visual deficits in persons with
PD, it is not surprising that the effect of dopamine on vision
in PD also remains conflicting. Impairments in low level visual
processing show limited response to treatment with levodopa (2,
3), and other symptoms such as dry eyes and inflammation of the
inner eyelidmay bemore likely causes of these deficits (3). In high
level visual processing, research is limited regarding the effects
of dopaminergic medication. Dopaminergic medication has been
shown to play a role in working memory more generally (13), but
the effects on visual working memory remain unknown. There
are limited reports on the effect of dopaminergic medication on
either object or facial recognition and mental rotation.
Thus, the purpose of this study was to examine performance
on cognitive vision tasks in persons with PD and the effects of
levodopa on these tasks. Two aims were addressed. The first was
to use any observed performance differences between individuals
with PD and their healthy counterparts across tasks to determine
where visual processing might be breaking down. The second
was to determine the extent to which performance on visual
tasks varies between ON-meds and OFF-medications states.
Accordingly, five experiments were designed to assess cognitive
vision that recruits processing resources at various levels. It
is hypothesized that persons with PD will show differences in
performance across all five visual tasks compared to HOAs, and
that levodopa will improve performance.
MATERIALS AND METHODS
Participants
Fourteen participants with a diagnosis of PD (Age: M = 71.1,
S.D. = 5.8; five Female, nine Male; Education = 15.0 years) and
14 age- and sex-matched HOAs (Age: M = 70.1, S.D. = 4.9; five
Female, nine Male; Education= 15.8 years) completed the study.
The PD diagnosis was confirmed by the participant’s treating
neurologist ormovement disorders specialist. The two groups did
not differ significantly in age (p = 0.81) or years of education (p
= 0.51). Inclusion criteria for all participants included normal or
corrected-to-normal vision as determined by an eye appointment
within the last 12 months. Additional inclusion criteria for
participants with PD was that they were currently taking a stable
dose of levodopa for at least the last 30 days. Exclusion criteria
included evidence of cognitive impairment (Mini Mental Status
Exam < 24) and/or depression (Geriatric Depression Scale >
5). See Table 1 for participant demographics. All participants
provided informed consent, and the study was approved by the
Institutional Review Board at Iowa State University.
Protocol
Both the HOAs and participants with PD completed two
sessions of visual processing testing during the same day: a
morning session (T1) and an afternoon session (T2). Both groups
completed all five visual tasks once during each session, and
a 1-h break was provided between the two sessions. Prior to
T1, participants with PD were asked to abstain from their
morning dose of all parkinsonian medications, resulting in a 12-
h withdrawal from medication. HOAs did not abstain from any
medications, and participants with PD did not abstain from any
non-Parkinsonianmedications. After T1 ended, participants with
PD were asked to take 1.5 times their standard dose of levodopa
while continuing to abstain from any other antiparkinsonian
medications. T2 started 1 h after taking the medication. HOAs
did not take any medication after T1.
For both T1 and T2 sessions, all participants completed five
visual processing tasks. Prior to completing the five tasks, all
participants completed a computerized task designed to help
them acclimate to their surroundings and familiarize them with
the format of the experimental tasks. Each of the 20 trials
in the acclimation task consisted simply of the simultaneous
presentation of two photographic images on a computer screen,
which were either family photographs or landscapes with no
people present. Participants were asked to indicate whether the
two images were the same or different by pressing one of two keys
on a standard keyboard. Images in the “Same” condition were
always identical, and images in the “Different” condition always
consisted of one family photo and one landscape to maximize
ease of judgement. Participants were given as long as they needed
to make a decision on each trial, and whichever keys on the
keyboard corresponded to “same” and “different” (either z or m)
remained constant for all tasks for the remainder of the study.
Once they had completed the acclimation task, participants
proceeded to complete all five of the computerized visual tasks.
Due to the number of trials in Experiment 1, this task was divided
into three parts with each administered separately. The three
parts of the Experiment 1 task and the other four experiment
tasks were all pooled and administered in random order. For
the T2, all participants completed the same visual tasks from T1,
except the acclimation task. All tasks were again administered in
random order.
Prior to completing the visual tasks during T1, all participants
with PD completed the motor portion of the Unified Parkinson’s
Disease Rating Scale (UPDRS). After the visual tasks were
completed in T2, the full version of the UPDRS was completed by
the PD group. The total score was used as an index of their overall
disease progression and is shown in Table 1. The motor scores
were used as an index of the effect of their levodopa medication.
The UPDRS was scored by a trained rater.
Visual Tasks Description
All visual tasks have been used in previous research (14–16). Task
1, Line Discrimination, consisted of pairs of white line segments
set against a black background (Figure 1A). Each trial began with
a blank screen that persisted for 1 s, followed by the simultaneous
presentation of two white horizontally aligned line segments. On
each trial, one line segment was rotated in the picture plane
between 0 and 90◦ from horizontal by some multiple of 10 (e.g.,
10, 20, 30◦, etc.). On half of the trials, the second line segment
was at the same angle as the first (i.e., rotated at 0◦ with respect
to the first segment) while on the other half of trials the second
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TABLE 1 | Participant demographics.
Healthy older adults Individuals with Parkinson’s disease
ID Gender Age Education
(yrs)







103 F 65 18 R 1 F 64 14 R 15 Right 6
109 M 75 18 R 2 M 77 12 R 67 Right 10
114 M 74 12 R 3 M 77 16 R 27 None 4
104 M 72 18 L 4 M 70 14 R 24 Right 11
101 F 69 12 R 5 F 70 12.5 R 51 None 7
119 M 63 12 R 6 M 61 24 R 63 Right 13
110 M 64 14 R 7 M 62 12 R 33 Left 6
118 F 67 12 R 8 F 70 12 R 46 None 12
102 M 67 20 R 9 M 67 16 R 39 Left 7
120 F 76 20 R 10 F 77 12 R 58 Right 8
112 M 66 16 R 12 M 67 16 R 65 Right 8
117 M 75 16 R 13 M 77 20 R 56 None 4
116 M 70 18 R 14 M 73 14 R 31 Left 16
106 F 78 16 R 15 F 75 16 R 41 Left 10
Average: 70.07 15.86 Average: 70.5 15.04
ID, Identification; F, female; M, male; R, right; L, left; yrs, years; UPDRS, Unified Parkinson’s Disease Rating Scale; MAS, more affected side.
line segment was rotated between 10 and 90◦ with respect to
the first, again by some multiple of 10◦. The task consisted of
180 trials, but was administered in three installments of 60 trials
each to minimize any effects of fatigue or proactive interference.
Each of the three installments of this task was divided into
blocks of 15 trials, between which the experiment paused and
encouraged participants to take a break for as long as they liked
prior to resuming.
The second task, Object Discrimination, began with a blank
screen that persisted for 1 s, followed by the simultaneous
presentation of two tube sculptures slightly offset about the
horizontal axis (Figure 1B). The stimuli for task two were
modeled on a set utilized by Logothetis et al. (14) and were
created as a series of eight points that would fall within the surface
of a cylinder measuring 20 units high and 10 units in diameter
(i.e., all were equidistant from a central, vertical axis). These eight
points were connected in serial order to form a figure composed
of seven line segments. The set of points was constrained so that
line segments formed by connecting them would be limited to
between 4 and 10 units, and angles formed by adjacent segments
were limited to between 90 and 120◦. Once each set of points was
calculated and drawn using a Python script, they were rejected
if the resulting figures contained line segments that intersected,
or if the figures were not sufficiently tall (i.e., at least 16 units on
the vertical axis). Once each set of points had been finalized, they
were rendered in MatLab2016b (https://www.mathworks.com/
products/matlab.html). Conversion of these 3D-rendered images
into.png files suitable for ePrime 2.0 was accomplished using
a free open source graphics program called Blender (https://
www.blender.org/). Seventy-two trials were completed in four
equal-sized blocks with rest in between each block.
The procedure for task three was identical to task two except
for the stimuli used. For this Facial Discrimination task, stimuli
were generated from a series of photographs of human faces
collected from Google images (Figure 1C). All photographs were
required to have closed mouths and neutral expressions. Half
of these photos were of men and half were of women. While
the rendering process likely obscured any features that would
have facilitated visual categorization into demographic groups,
effort was made to ensure that the initial images represented a
broad (though incomplete) cross section of individuals. Thus,
for each gender category, photographs were further selected on
the basis of race and region of origin so that the full stimulus
set contained equal numbers of Asian, Australian Aboriginal,
Black, Caucasian, Latina/o, andMiddle Eastern individuals. Once
these photos were collected, a computer program called FaceGen
(https://facegen.com/) was used to render each face onto a 3-
dimensional head. This process removed all of the color and
hair from the faces so that each could be distinguished only
through inspection of its structural features. The process also
allowed all heads to be rendered at a constant height, so that
they could not be distinguished on the basis of how closely
their edges came to the border of the screen. Once these 3-
dimensional heads were rendered, they were exported as.obj files
and opened in Blender (http://www.blender.org), a freeware 3D
art program that allowed for precise manipulation of the heads in
3-dimensional space. Seventy-two trials were completed in four
equal-sized blocks with rest in between each block.
For the fourth task, Visual Working Memory, face and object
stimuli were generated by the same methods used in tasks two
and three, but new sets of these stimuli were created for this
experiment, such that no face or tube sculpture was reused across
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FIGURE 1 | Example of visual stimuli used for the line discrimination task (A), the object discrimination task (B), the facial discrimination task (C), and the object
rotation task (D).
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tasks or sessions (Figures 1B,C). This task was composed of 72
trials. Each trial in this task comprised a study period and a test
period. During the study period (2,500ms), participants were
asked to study and remember an object or face presented on
the screen. The study period was followed by one of the three
designated delay intervals. One-third of the trials had a 3,000ms
delay, while another one-third had a 1,000ms delay, and another
third had a 5,000ms delay. The delay was followed by a test period
in which participants were asked to indicate whether the object
or face that subsequently appeared on the screen was the same
as or different than the stimulus presented in the study period.
Seventy-two trials were completed in four equal-sized blocks with
rest in between each block.
The stimuli used in task five, Object Rotation, were a set
of perspective line drawings of novel 3-dimensional objects
(Figure 1D). This stimulus set was developed by Ganis and Kievit
(15) as an update to a classic stimulus set developed by Shepard
and Metzler (16). The objects consisted of 7–11 cubes serially
connected face-to-face in such a way that four 90◦ angles were
formed along the length of the object. On each trial, two of
the line objects were simultaneously presented on the screen,
aligned horizontally. On half of all trials, both stimuli had the
same structural description, while on the other half one of the
four angles were changed in orientation to slightly alter the
figure. Further, stimuli were rotated with respect to one another
by either 0, 50, 100, or 150◦ about the Y-axis. This task was
composed of 36 trials delivered in four equal-sized blocks with
rest in between each block.
For all tasks, half of all participants pressed the “z” key if
they believed that the two visual stimuli were the same and
pressed the “m” key if they believed the two visual stimuli were
different, while the other half of participants received the reverse
key mapping. There was no pre-set time limit on each trial, so the
stimuli remained on the screen until the participants responded.
Data Analysis
For each task, the percent correct was determined. For Task 1
(Line Discrimination), a 2 (Group: PD vs. HOA) × 2 (Session:
T1 vs. T2) × 3 [Line Angle: Small (10, 20, and 30◦), Medium
(40, 50, and 60◦), and Large (70, 80, and 90◦)] mixed factorial
ANOVA was completed. For tasks 2 and 3 (Object and Facial
Discrimination, respectively) the effects of PD pathology and
levodopa treatment were examined using a 2 (Group: PD vs.
HOA) × 2 (Session: T1 vs. T2) ANOVA. For task 4 (Visual
Working Memory), the effects of PD pathology and levodopa
treatment on visual working memory were examined using a 2
(Group: PD vs. HOA) × 2 (Session: T1 vs. T2) × 2 (Stimulus
Type: Objects vs. Faces) × 3 (Delay: 1,000, 3,000, and 5,000ms)
mixed factorial ANOVA. For task 5 (Object Rotation), the effect
of PD pathology and levodopa treatment onmental rotation were
examined using a 2 (Group: PD vs. HOA)× 2 (Session: T1 vs. T2)
× 2 (Identity: Same vs. Different)× 4 (Angle: 0, 50, 100, and 150)
mixed factorial ANOVA. Post-hoc analyses were completed with
Tukey’s Honestly Significant Difference tests, and significance
was set at α = 0.05.
For the motor UPDRS, a within subjects t-test was completed
to determine if there was an effect of medication on clinical
motor symptoms in the participants with PD. In addition,
difference scores for all tasks (afternoon session scores minus
morning session scores) and for the motor portion of the
UPDRS were calculated. Pearson Correlations were completed to
examine the relationship between levodopa administration and
FIGURE 2 | Mean and standard error for all tasks for both groups and for both sessions. Asterisks designate a significant group effect at p < 0.05, and the pound
sign indicates a significant session effect at p < 0.05.
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task performance in persons with PD. Significance was set at α
= 0.05.
RESULTS
Figure 2 shows the mean and standard error for both groups for
both sessions across each task. Across tasks, participants with PD
performed worse than the HOAs. However, results did not differ
between sessions, except for line discrimination. This would
indicate that, in general, for participants with PD, medication
did not affect performance on these tasks. Statistical results are
reported below for each task (Table 2).
For line discrimination (task 1), a main effect of group, F(1, 26)
= 13.45, p = 0.001, η2p = 0.341, with the HOA group (M =
97.78%, SE = 0.96%) making more correct judgments than the
PD group (M = 92.78%, SE = 0.96%) was revealed. There
was also a main effect of session, F(1, 26) = 5.24, p = 0.03,
η
2
p = 0.168, with participants across groups performing better
in T1 (M = 95.91%, SE = 0.65%) than T2 (M = 94.64%, SE
= 0.81%). Additionally, a main effect of angle was revealed,
F(2, 52) = 23.491, p < 0.001, η
2
p = 0.475, with participants across
groups performing worse on trials with small (10–30◦) angles of
rotation (M = 89.58%, SE = 1.69%) than either medium (40–
60◦) rotations (M = 98.63%, SE = 0.37%) or large (70–90◦)
rotations (M = 97.62%, SE = 0.70%). The interaction between
angle and group was also significant, F(2, 52) = 4.34, p = 0.02,
η
2
p = 0.143. Specifically, both groups performed more poorly on
small rotation than medium rotation trials (PD: p < 0.001; HOA:
p= 0.04), but only the PD group also performed more poorly on
small rotation than large rotation trials (PD: p < 0.001; HOA: p
= 0.07) (Figure 3).
For object discrimination, there was a main effect of group,
F(1, 26) = 6.37, p = 0.02, η
2
p =.197, with the HOA group (M =
99.45%, SE = 0.45%) scoring higher on the task than the PD
group (M = 97.87%, SE = 0.45%). There was no main effect
of session. However, the interaction between session and group
was significant, F(1, 26) = 5.65, p = 0.03, η
2
p = 0.178, with the
PD group performing better in the morning than the afternoon,
p = 0.02, but no corresponding difference in the HOA group,
p= 0.45.
For face discrimination, the results also showed a main effect
of group, F(1, 26) = 10.71, p < 0.01, η
2
p = 0.292, with the HOA
group (M = 95.39%, SE= 1.51%) scoring higher on the task than
the PD group (M = 88.39%, SE = 1.51%). No other effects or
interactions were significant.
For visual working memory, the results showed a main effect
of group, F(1, 26) = 4.62, p = 0.04, η
2
p = 0.151, with the HOA
group (M = 80.75%, SE = 1.50%) scoring higher than the PD
group (M = 76.19%, SE = 1.50%). There was a main effect of
stimulus type, F(1, 26) = 224.20, p < 0.001, η
2
p = 0.896, with
participants across groups performing better on object trials (M
= 91.17%, SE = 1.47%) than face trials (M = 65.77%, SE =
1.24%). There was also a main effect of delay, F(2, 52) = 6.98, p
< 0.01, η2p = 0.212, with participants across groups performing
better on both the 1,000ms delay trials (M = 80.21%, SE =
1.57%) and 3,000ms delay trials (M = 81.10%, SE= 1.30%) than
on the 5,000ms delay trials (M = 74.11%, SE = 1.84%) (p =
0.04 and p = 0.01, respectively) (Figure 4). No other effects or
interactions were significant.
For object rotation, there was a main effect of group, F(1, 24)
= 12.043, p < 0.01, η2p = 0.334, with the HOA group making
more correct judgments (M = 93.63%, SE = 2.31%) than the
PD group (M = 82.32%, SE = 2.31%). There was also a main
effect of rotation angle, F(3, 72) = 3.25, p = 0.03, η
2
p = 0.119.
Both groups performed better on trials with 0◦ of rotation (M
= 91.99%, SE = 1.96%) than trials with 50◦ (M = 88.36%, SE =
2.38%), 100◦ (M = 85.68%, SE = 2.00%), or 150◦ (M = 85.90%,
SE= 2.26%) of angular rotation (p= 0.02, p= 0.02, and p= 0.03,
respectively) (Figure 5). No other effects or interactions rose to
the level of significance.
Motor UPDRS
A within subjects t-test showed a significant effect of levodopa
administration, t = −3.08, p < 0.01, with symptoms being
more severe in the morning (M = 26.86, SD = 13.83) than
in the afternoon (M = 22.12, SD = 11.38). However, there
were no significant associations between the change in motor
UPDRS score and change in any visual processing task (Line
Discrimination, p= 0.94; Object Discrimination, p= 0.86; Facial
discrimination, p = 0.86; Visual Working Memory, p = 0.71;
Object Rotation, p= 0.63).
DISCUSSION
The purpose of this study was to examine cognitive visual
processing in individuals with PD and how resulting symptoms
respond to levodopa. The aims were to determine where in
the pathway visual processing might be breaking down and the
extent to which performance on visual tasks varied between
ON-medication and OFF-medication states. As anticipated,
the PD group performed significantly worse than the HOA
group across all tasks. However, performance deficits in the
PD group were unaffected by the administration of levodopa,
suggesting that mechanisms other than dopamine depletion may
be responsible for impairments in cognitive vision. Further,
given that there were no dramatic changes in mean difference
between groups across tasks, the implications for where in the
pathway visual processing is breaking down requires a somewhat
nuanced interpretation.
Differences Between Groups, but Not
Medication, Why?
The striatum in the basal ganglia has the highest expression of
dopamine receptor mRNA (both D1 and D2) of any region of the
human brain (17) and dysfunction of dopaminergic signaling in
the striatum is believed to be the principal cause of the majority
of motor and cognitive deficits in PD (18). Thus, to the extent
that visual tasks recruit processing resources from the basal
ganglia, it was expected that dopamine depletion in the basal
ganglia associated with PD would lead to deficits in the visual
processing tasks used in this study. The results of this study did
show that persons with PD performed worse on cognitive vision
tasks as compared to healthy older adults, which may support
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TABLE 2 | Statistical results.
Task 1: F df p Partial eta squared Observed power
Session 5.241 1 0.030 0.168 0.597
Group 13.451 1 0.001 0.341 0.942
Angle 23.491 2 0.000 0.475 1.000
Session × Group 4.013 1 0.056 0.134 0.488
Session × Angle 3.151 2 0.051 0.108 0.580
Group × Angle 4.338 2 0.018 0.143 0.728
Session × Group × Angle 1.150 2 0.324 0.042 0.242
Task 2: F df p Partial eta squared Observed power
Session 1.680 1 0.206 0.061 0.239
Group 6.369 1 0.018 0.197 0.681
Session × Group 5.648 1 0.025 0.178 0.629
Task 3: F df p Partial eta squared Observed power
Session 0.079 1 0.781 0.003 0.058
Group 10.708 1 0.003 0.292 0.883
Session × Group 0.040 1 0.843 0.002 0.054
Task 4: F df p Partial eta squared Observed power
Session 0.072 1 0.791 0.003 0.058
Group 4.619 1 0.041 0.151 0.544
Stimulus type 224.202 1 0.000 0.896 1.000
Delay interval 6.976 2 0.002 0.212 0.912
Session × Group 0.347 1 0.561 0.013 0.088
Session × Stimulus type 0.118 1 0.734 0.005 0.063
Session × Delay interval 0.565 2 0.572 0.021 0.139
Group × Stimulus type 2.682 1 0.114 0.094 0.351
Group × Delay interval 0.259 2 0.772 0.010 0.089
Stimulus type × Delay interval 2.247 2 0.116 0.080 0.437
Session × Group × Stimulus type 0.209 1 0.651 0.008 0.073
Group × Stimulus type × Delay interval 0.159 2 0.853 0.006 0.073
Session × Group × Delay interval 1.306 2 0.280 0.048 0.270
Session × Stimulus type × Delay interval 0.274 2 0.761 0.010 0.091
Session × Group × Stimulus type × Delay interval 1.519 2 0.228 0.055 0.309
Task 5: F df p Partial eta squared Observed power
Session 0.133 1 0.719 0.005 0.064
Group 12.043 1 0.002 0.334 0.914
Identity 0.125 1 0.727 0.005 0.063
Angle 3.245 3 0.027 0.119 0.723
Session × Group 1.401 1 0.248 0.055 0.206
Session × Identity 0.487 1 0.492 0.02 0.103
Session × Angle 1.871 3 0.142 0.072 0.466
Group × Identity 0 1 1.000 0 0.05
Group × Angle 0.428 3 0.734 0.018 0.131
Identity × Angle 1.114 3 0.349 0.044 0.289
Session × Group × Identity 0.92 1 0.347 0.037 0.151
Session × Identity × Angle 1.42 3 0.244 0.056 0.362
Identity × Angle × Group 0.382 3 0.766 0.016 0.122
Angle × Session × Group 0.652 3 0.584 0.026 0.181
Session × Group × Identity × Angle 0.339 3 0.797 0.041 0.113
this notion. However, there were no significant improvements in
performance after the administration of levodopa across all tasks.
This would suggest that other mechanisms may be involved in
cognitive vision impairment in persons with PD.
More recent research indicates that the pathways between
the basal ganglia and the visual pathway are involved in
the learning aspects of processing visual stimuli. Specifically,
the occipitotemporo-neostriatal pathway has been implicated
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FIGURE 3 | Mean and standard error for the line discrimination task. The interaction between group and angle is shown. Asterisks designate significance at p < 0.05.
in learning visual associations based on reward, such that
damage does not lead to impairments in fundamental visual
discrimination of stimuli (19). In contrast, the occipitotemporo-
ventral striatum pathway has been implicated in the assignment
of value to stimuli (20). This finding has been supported by
imaging studies of humans indicating that the ventral striatum
shows selective activation for rewarded outcomes (21). Taking
together, this evidence suggests PD pathology in the basal
ganglia would be more likely to disrupt learning of object
associations and values and may explain the lack of medication
effect on the object discrimination tasks in this study. This
finding is in keeping with previous research. Lange et al.
found that dopaminergic modulation had no significant effect
on performance of spatial or pattern recognition memory
tasks, simultaneous or delayed match-to-sample tasks, or visual
associative learning tasks (13). Moreover, Pillon et al. found no
difference in performance on a ventral pathway-dependent visual
task when individuals were in on vs. off medication states (22).
Thus, the lack of dopaminergic modulation on the high level
cognitive vision tasks (e.g., object discrimination) in this study
may suggest that other non-dopaminergic mechanisms underlie
the control of these tasks, but are nonetheless still affected by
PD pathology.
The significant difference between persons with PD and
HOAs across all tasks revealed in this study may suggest that
impairments in high level cognitive visual tasks are simply the
result of deficits in more basic visual processing that are not
dependent upon dopaminergic activity. For instance, researchers
have reported symptoms such as decreased blink rate, dry eyes,
blepharospasm (uncontrolled spastic movements of the eyelids
and brows, bilaterally) that are linked to ocular surface irritation
in persons with PD (3). Other researchers have also reported
the presence misfolded and phosphorylated α-synuclein in the
retinas of individuals with PD (4). Together, these symptomsmay
account for at least some of the acuity and contrast sensitivity
deficits observed in PD that may be unrelated to dopamine.
Alternatively, PD may lead to impaired dopaminergic signaling
in areas of the visual system without any direct involvement of
the basal ganglia. Dopamine receptors have been observed in a
wide range of visual areas involved in object identification and
recognition, including the retina (23), lateral geniculate nucleus,
primary visual cortex, and prefrontal cortex (16). In the human
retina, dopamine function is thought to contribute to light
adaptation and establishing the center-surround organization of
retinal receptive fields that facilitates edge detection (24, 25).
Moderate to high levels of D2 receptor mRNA were identified in
the lateral geniculate nucleus, while moderate to high levels of
D1 receptor mRNA were identified in the primary visual cortex
(V1) (16). Thus, dopamine depletion in these areas might lead to
deficits in perception of visual features to which the retinal fields
of the lateral geniculate nucleus and primary visual cortex are
most responsive (e.g., bars of light of particular lengths, either
stationary, or moving perpendicular to their long axes) (26).
These lower level visual deficits may then affect downstream
processing of high level cognitive vision.
A second explanation for the differences between PD and
HOA groups, but no improvement with levodopa may be due
to diffuse neural atrophy. For instance, studies have shown that
PD is associated with microstructural changes in both gray
and white matter that appear to scale with disease severity
(27), and may be associated with mild cognitive impairment
(27, 28). Moreover, the changes in gray matter volume are in
regions that have implications for visual processing (9). Patients
with PD who have developed dementia also show decreased
volume in the occipital cortex (29). Koh et al. (30) found
that abnormal stereopsis in individuals with PD was associated
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FIGURE 4 | (A) Mean and standard error for memory of objects and faces across both groups on the visual working memory task. (B) Mean and standard error for
visual working memory across both groups for each time delay. Asterisks designate significance at p < 0.05.
with significantly reduced gray matter in the extrastriate visual
cortex. Pereira et al. (9) found that decreased performance
on a face recognition task was associated with decreased gray
matter volume in the fusiform gyrus, parahippocampus, middle
occipital gyrus, and inferior frontal gyrus in persons with PD.
Decreased performance on a visual form discrimination task was
associated with gray matter losses in the superior parietal and
occipital lobes, as well as in the inferior and middle frontal gyri.
Finally, decreased performance on a test of memory for faces was
associated with gray matter losses in the right parahippocampus
(9). It is therefore likely that at least some of the visual deficits
observed in this study may also be at least partially accounted for
by neural atrophy.
Finally, if deficits in basic visual processing in this study
are dependent on dopaminergic processing, there remains the
question of why dopaminergic medication did not improve
performance. Research has shown that the basal ganglia has
fairly robust mechanisms to compensate for the loss of dopamine
in PD, and as a result symptoms of dopamine depletion in
the basal ganglia which lead to a clinical diagnosis of PD
are not likely to be observed in the early stages of pathology
or injury (31). If dopamine circuitry in the visual system
lacks similar compensatory mechanisms, it may be that visual
symptoms become refractory to treatment with dopamine
precursor medications while the same drugs remain efficacious
for basal ganglia-dependent pathology.
Breakdown in the Visual Processing
Pathway
This study was designed to employ tasks that could provide
evidence concerning which areas the visual system might be the
source of any observed visual impairment. Specifically, each of
the five visual tasks in the current study have been found in
previous studies to recruit a slightly different constellation of
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FIGURE 5 | Mean and standard error for object rotation across both groups for each angle of rotations. Asterisks designate significance at p < 0.05.
visual areas. If PD pathology had disproportionately affected any
of these areas, we would have predicted that some appreciable
number of individuals in the PD group would have performed
at or near chance for tasks that required processing in this area
while all members of the HOA group remained comparatively
unaffected. For example, if the prefrontal cortex deteriorated
significantly in PD while the ventral visual pathway itself
was largely spared, we would predict that members of the
PD group would perform at or near chance on the visual
working memory and object rotation tasks while showing
little or no deficit on the first three discrimination tasks.
On the other hand, if PD pathology was specific to early
visual areas such as the retina or V1, we would expect
members of the PD group to perform close to chance on all
five tasks.
However, no dramatic drop to chance level was observed
for the PD group for any task. Instead, the PD group
performed significantly worse than the HOA group on all
tasks while never showing a profound deficit on any one
task. One way to account for the pattern of results observed
in this study would be to postulate that two regions critical
for these tasks were particularly susceptible to PD pathology:
one in the early visual system and one in motor cortical
regions. The former would account for the small but persistent
group differences observed in the first four tasks. It may
simply be that whatever damage produced the impaired fine
visual discrimination observed in the line discrimination task
produced a similar impairment in the discrimination of the
object and face stimuli used in this study. On the other hand,
impairment of the motor cortical regions would account for
the increase in effect of group observed in the object rotation
task. This position was supported by research suggesting a role
for motor cortical areas in mental simulation and emulation
(32, 33) and research indicating that these areas show altered
or diminished function in PD (34, 35). However, no brain
imaging techniques were used in this study to confirm the
role of the motor cortex in visual impairments in persons
with PD.
Limitations
There are limitations to this study. Participants were not
screened for motor fluctuations. Some participants may have
been under the influence of a long-duration levodopa benefit,
which may obscure the effect of levodopa on the visual tasks.
While the 12 h wash out is a common practice in previous
PD research, 12 h may not have been long enough to fully
washout the effects of levodopa or any additional medication
participants were taking. These limitations may explain the
lack of effect of levodopa on the visual tasks in this study.
However, it is important to note that there was still an effect
of levodopa on UPDRS motor symptoms. The wash out period
or long-duration benefit may affect visual symptoms differently
than motor symptoms. In addition, since cognitive testing
was not completed, the contribution of cognitive impairment
to impairments in cognitive vision in this sample cannot be
ruled out. Finally, the sample size was small, which limits the
generalizability of the results.
CONCLUSION
This study was designed to investigate the effects of dopamine
and dopaminergic medications on impairments to high-level
vision in PD. Despite the key role that dopamine depletion
plays in much of the pathology of PD, the results of the
present study provide evidence that modulation of dopamine
levels may not improve or impair cognitive vision in individuals
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with PD, which represents a novel finding in visual research.
These results indicate that continued research is needed to
fully understand vision impairments and the most beneficial
therapeutic strategy to treat this impairment in persons
with PD.
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